SCHEMBL4792895

SCHEMBL4792895

C[C@@H]1CCCCCCN(C)C1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.40
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
KDM4E B2RXH2 1/20 0.36
CHRM5 P08912 1/20 0.36
ADRA2C P18825 1/20 0.36
LMNA P02545 2/20 0.34
ALDH1A1 P00352 1/20 0.34
KAT2B Q92831 2/20 0.33
CYP1A2 P05177 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16510900 1.00 ACHE (0.40) ACHESLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL20980965 1.00 ACHE (0.40) ACHESLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL20827195 1.00 ACHE (0.40) ACHESLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL16131669 1.00 ACHE (0.40) ACHESLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL12947444 1.00 ACHE (0.40) ACHESLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4791210 1.00 ACHE (0.40) ACHESLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL15038217 0.97
SCHEMBL19533310 0.97
SCHEMBL6853488 0.97
SCHEMBL81240 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120108582-A1 Fused substituted aminopyrrolidine derivative DAIICHI SANKYO COMPANY, LIMITED 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108582-A1 Fused substituted aminopyrrolidine derivative NQO2, QDPR, IL4I1 ACHE 4059/4885SLC6A2 3313/4885SLC6A4 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.